By: 26 May 2020
Rivaroxaban proves superior to heparin in preventing blood clots after common orthopaedic surgeries

The direct oral anticoagulant rivaroxaban dramatically cut the likelihood of serious venous thromboembolism (VTE) in people recovering from lower limb orthopaedic surgery and requiring immobilisation, in comparison with enoxaparin, another anticoagulant agent, according to research presented at the American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).

The new data revealed that rivaroxaban cut the risk of major VTE by 75% without increasing the risk of bleeding, a common concern in patients taking a blood thinner. This international, double-blind, randomised controlled trial is the first to compare rivaroxaban against enoxaparin, a low molecular weight heparin, for clot prevention in people recovering from non-major orthopaedic surgeries who often must restrict movements of the affected limb for a period of time to promote healing. However, even a brief period of reduced mobility can heighten a person’s risk of developing dangerous blood clots that can lead to deep vein thrombosis (DVT), a condition where clots form in the veins of the legs, or pulmonary embolism, when clots travel and get lodged in the lungs.

“We must prevent VTEs in these patients because some can lead to pulmonary embolism, which can be fatal,” said Dr Nadia Rosencher, Senior Consultant and Anesthesiologist at Paris University in France, and one of the study authors. “This study represents a major step forward in our treatment of patients after many orthopaedic procedures because it proves that we can more effectively prevent thrombosis with a once-daily oral medication versus a daily injection with the same safety.”

Rosencher said taking injections of enoxaparin can be very cumbersome for patients, who sometimes require a nurse to help administer the medication. Additionally, this is a young population with a median age of 40 years, who often need to get back to work or caring for a family without added complications.

Rivaroxaban works by blocking the activity of the clotting protein factor Xa. It’s known to be a strong anticoagulant, so researchers said they were somewhat surprised and reassured to find that bleeding risk was the same as with enoxaparin.

While most contemporary clinical guidelines recommend using anticoagulants to prevent blood clots after major orthopaedic surgeries, including total knee and total hip replacements, that put patients at higher risk for VTEs, there is less agreement about prophylactic thrombosis treatment in patients at moderate risk for clots—for example, those undergoing ankle surgery, ligament repair or knee arthroscopy. Millions of people in the US undergo these procedures each year and may need blood thinning to prevent clots from forming.

“In Europe